Research Institute timeline

Since its establishment in 2005, the HonorHealth Research Institute has achieved many accomplishments. They include:

More than 5,000 patients receiving expanded care through clinical trials.
More than 200 investigators developing and conducting research in the HonorHealth system.
Completing more than 500 clinical trials.
Impacting the value of science and medicine through hundreds of publications.

Accomplishments by year:

Scottsdale runner received the first fully dissolving heart stent approved by FDA after clinical trials performed at the institute.
Stand Up 2 Cancer grant award.

Awarded a $200,000 grant from the Flinn Foundation to investigate the relationship of the microbiome and ventilator-associated pneumonia.
FDA approval of the Maestro system for vagal nerve block and weight management.
FDA approval for the Reshape double gastric balloon, a nonsurgical device for treatment of obesity.

Received FDA approval for the drug combination of Gemcitabine and Abraxane trial, which became the standard for using drug combinations for cancer treatments.
Launched RADAR (rapid detection and assessment of response), a program using new imaging technologies to look at patients’ responses to targeted therapy. Established with a $100,000 grant from the Scottsdale Industrial Development Authority.

Received the second-fastest FDA drug approval in history for the Hedgehog Pathway-Erivedge for metastatic basal cell cancer.

Began the Bariatric Research Program with two clinical trials for specialized devices for obesity.
Obtained FDA approval for the use of Xience V Everolimu Eluting Coronary Stent System for coronary disease.
Obtained FDA approval for the use of rivaroxaban for stroke prevention in patients with afibrillation.

Received an $18 million Stand Up to Cancer Award for the Pancreatic Cancer Dream Team. The institute was the first site to complete and publish positive results from the trial, a collaboration between Johns Hopkins, the Salk Institute, Columbia University and University of Pennsylvania.

Completed construction of the building and opened the Bisgrove Research Pavilion.
Established research as a requirement to the first American College of Surgeons Level 1 trauma designation at Scottsdale Healthcare Osborn Medical Center.

Launched the Drug Development Scholar Program to develop the next generation of clinical investigators.

Accepted a $5 million donation from the Stardust Foundation.
Established Phase I oncology clinical trial program infrastructure.
Began Phase I study of gemcitabine combined with abraxane clinical trial for treatment of pancreatic cancer.
Began the Bisgrove Trial, the first one developed in collaboration with TGen to investigate and prove the use of molecular profiling to target tumors and select therapies.
Began Phase I Hedgehog Pathway clinical trial for the treatment of metastatic solid tumors, successfully treating the first person in the world.

Established as an institute with a $4.5 million Piper Trust grant to develop biosciences and establish personalized medicine in oncology at Scottsdale Healthcare.
Launched a relationship with University of Arizona Cancer Center to bring oncology clinical trials and expertise to Scottsdale.
Named Daniel Von Hoff, MD, as chief scientific officer.
Established a partnership with the Translational Genomics Research Institute (TGen).